- Home
- AFCG vs BDSX Comparison
AFCG vs BDSX Comparison
Compare AFCG & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFCG
- BDSX
- Stock Information
- Founded
- AFCG 2020
- BDSX 2005
- Country
- AFCG United States
- BDSX United States
- Employees
- AFCG N/A
- BDSX N/A
- Industry
- AFCG Real Estate Investment Trusts
- BDSX Precision Instruments
- Sector
- AFCG Real Estate
- BDSX Health Care
- Exchange
- AFCG Nasdaq
- BDSX Nasdaq
- Market Cap
- AFCG 127.4M
- BDSX 115.4M
- IPO Year
- AFCG 2021
- BDSX 2020
- Fundamental
- Price
- AFCG $4.62
- BDSX $0.26
- Analyst Decision
- AFCG Buy
- BDSX Strong Buy
- Analyst Count
- AFCG 7
- BDSX 5
- Target Price
- AFCG $11.00
- BDSX $1.75
- AVG Volume (30 Days)
- AFCG 228.5K
- BDSX 2.9M
- Earning Date
- AFCG 08-06-2025
- BDSX 08-06-2025
- Dividend Yield
- AFCG 22.41%
- BDSX N/A
- EPS Growth
- AFCG 84.02
- BDSX N/A
- EPS
- AFCG 0.96
- BDSX N/A
- Revenue
- AFCG $41,036,509.00
- BDSX $74,463,000.00
- Revenue This Year
- AFCG N/A
- BDSX $17.29
- Revenue Next Year
- AFCG $17.96
- BDSX $29.33
- P/E Ratio
- AFCG $5.15
- BDSX N/A
- Revenue Growth
- AFCG N/A
- BDSX 35.76
- 52 Week Low
- AFCG $4.32
- BDSX $0.17
- 52 Week High
- AFCG $10.88
- BDSX $2.04
- Technical
- Relative Strength Index (RSI)
- AFCG 37.15
- BDSX 38.93
- Support Level
- AFCG $4.32
- BDSX $0.27
- Resistance Level
- AFCG $5.78
- BDSX $0.33
- Average True Range (ATR)
- AFCG 0.25
- BDSX 0.03
- MACD
- AFCG -0.08
- BDSX 0.01
- Stochastic Oscillator
- AFCG 15.75
- BDSX 19.54
About AFCG AFC Gamma Inc.
Advanced Flower Capital Inc is a commercial mortgage REIT that provides institutional loans to cannabis operators in the U.S. Through the management team's deep network and related credit and cannabis expertise. The company originates, structures, and underwrites loans secured by quality real estate assets, license value, and cash flows.
About BDSX Biodesix Inc.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.